Saeed Ahmed Memon: Can Hydralazine Stop Aggressive Brain Cancer Cells?
Saeed Ahmed Memon, Psychiatrist at Health Department Govt of SINDH Pakistan, shared a post on LinkedIn:
“Medical researchers at the University of Pennsylvania have recently unlocked the precise molecular secrets of Hydralazine, a cardiovascular medication that has been utilized globally for decades.
Scientists discovered that this established drug fundamentally works by blocking a specific oxygen-sensing enzyme known as ADO, which typically signals blood vessels to severely constrict when oxygen levels drop.
By actively shutting down this specific enzyme, the medication stabilizes cellular proteins and forces blood vessels to relax.
However, while mapping this exact cardiovascular mechanism, researchers stumbled upon an incredible secondary application regarding one of the most notoriously aggressive forms of brain cancer.
The exact oxygen-sensing pathway that constricts blood vessels is identically utilized by Glioblastoma tumors to survive and thrive in low-oxygen environments.
When scientists applied Hydralazine to these malignant cells, the medication did not kill them directly, but instead trapped the cancer in a dormant, non-dividing state known as senescence, abruptly halting the tumor’s growth.
This remarkable scientific breakthrough highlights the massive, untapped potential of repurposing established, safety-tested pharmaceutical compounds to combat highly complex oncological challenges.”
Stay updated with Hemostasis Today.
-
May 11, 2026, 13:32Muhammad Aqib Faizan: Pulsed Field Ablation Improves Procedural Time Compared to the Conventional Ablation in AF
-
May 11, 2026, 13:29Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology
-
May 11, 2026, 13:27Milano 2022: Where My Journey Began – Sergio Emanuel Kaiser
-
May 11, 2026, 13:15Vitor Ferreira: VeinPlanner Makes Complex Venous Planning More Efficient
-
May 11, 2026, 13:14Translating Bleeding Risk Models Into Everyday Practice – Thrombosis Canada
-
May 11, 2026, 12:59Munira Borhany: Latest Advances in JAK Inhibitors for Myelofibrosis
-
May 11, 2026, 12:53Muhammet Özbilen: Is the IV Iron Given to Hospitalized Patients Sufficient?
-
May 11, 2026, 12:52Ryan Rodarmer: Writing Through Aortic Disease and Medical Trauma
-
May 11, 2026, 12:51Megan Adediran: The Power of Global Collaboration in Hemophilia Care